Pipeline
Curexsys is currently pursuing the development of several programs in three indications. Programs in one indications are pursued non-exclusive with an industry partner. We focus on the generation of clearly defined, characterized and purified extracellular vesicles / exosomes from our proprietary iMSC lines derived from Evotec’s iPSC platform. While we will pursue some indications ourselves or together with a partner, our technology would also allow to explore the therapeutic and rejuvenating potential of exosomes in various other indications, which we offer for partnerships.
Ophthalmology
Development
Preclinical
Phase 1
Phase 2
Phase 3
Dermatology
Development
Preclinical
Phase 1
Phase 2
Phase 3
Skeletal diseases
Development
Preclinical
Phase 1
Phase 2
Phase 3
Technology